Trial reportFrontiers in immunology2018
IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.
Trial report in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.The Cochrane database of systematic reviews · 2024Pooled it
- Biomarkers of Cardiovascular Stress: A Historical Review.Journal of cardiovascular development and disease · 2026Review
- Single-cell transcriptomics and machine learning identify RNF144B and C5AR1 as immune-related molecular signatures and therapeutic targets in myocardial infarction.Genes & genomics · 2026Article
- Role of Interleukin-6 in Atherothrombosis and Myocardial Infarction.Current atherosclerosis reports · 2026Review
- Systemic immune-inflammation index, neutrophil to high-density lipoprotein ratio and pre-hospital delay: promising biomarkers for predicting the prognosis of patients with acute ST-elevation myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis.Cardiovascular diabetology · 2025Article
- Combined complement and coagulation activation in ST-elevation myocardial infarction: associations with myocardial injury and dysfunction.Frontiers in immunology · 2025Article
- Differential gene expression patterns in ST-elevation Myocardial Infarction and Non-ST-elevation Myocardial Infarction.Scientific reports · 2024Article
- Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence.Journal of clinical medicine · 2023Review
- The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches.International journal of molecular sciences · 2022Review
- Article
- Article
- Management of inflammation in cardiovascular diseases.Pharmacological research · 2021Review
- Weighted gene co-expression network analysis identifies specific modules and hub genes related to coronary artery disease.Scientific reports · 2021Article
- C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease.Pharmacogenomics and personalized medicine · 2021Article
- Disease Mechanisms of Perioperative Organ Injury.Anesthesia and analgesia · 2020Review
- Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.Clinical immunology (Orlando, Fla.) · 2020Article
- Covid-19: Time for a paradigm change.Reviews in medical virology · 2020Article
- COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.Annals of hematology · 2020Review
- In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.